Posts for Mineralys Therapeutics, Inc. ($MLYS)

Explore Mineralys Therapeutics' Q1 2023 financial report, highlighting IPO success, ongoing losses, and a 'Hold' investment recommendation amidst strong R&D focus.

Discover the latest Form 8-K filing by Mineralys Therapeutics, Inc. (NASDAQ: MLYS) detailing crucial updates and compliance information for February 12, 2025.

Discover crucial insights from Mineralys Therapeutics, Inc.'s 8-K filing on January 8, 2025. Stay informed on major events impacting shareholders and market performance.